08:00 , Feb 16, 2015 |  BioCentury  |  Emerging Company Profile

COX-ing cancer into submission

Euclises Pharmaceuticals Inc. is developing two COX-2 inhibitor programs, one via a prodrug approach and one using deuteration, which are designed to minimize the gastrointestinal side effects that curtailed development of first-generation inhibitors for cancer....
07:00 , Sep 15, 2014 |  BC Week In Review  |  Financial News

Euclises completes venture financing

Euclises Pharmaceuticals Inc. , St. Louis, Mo.   Business: Cancer, Inflammation   Date completed: 2014-09-09   Type: Venture financing   Raised: $1.3 million   Investors: Cultivation Capital; BioGenerator; Missouri Technology Corp.; Analytical Bio-Chemistry Laboratories Inc.;...
07:00 , Jun 28, 2010 |  BC Week In Review  |  Financial News

Galera Therapeutics completes venture financing

Galera Therapeutics LLC , St. Louis, Mo.   Business: Other   Date completed: 6/15/10   Type: Venture financing   Raised: $680,000   Investors: BioGenerator; Galera Angels; Analytical Bio-Chemistry Laboratories Inc.  ...